Engflag

Bexidermil

Quick links to important sections

Bexidermil

Bexidermil_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bexidermil

Quick Facts

Property Description
Active ingredient Trolamine Salicylate
Form Cutaneous Gel or Cream
Pharmacological class Topical Salicylate Analgesic
General purpose Local symptomatic pain relief
Origin Synthetic derivative

The Identity of Bexidermil: What Type of Medicine Is It?

Bexidermil is a medicinal product intended strictly for cutaneous (topical) administration, meaning it is applied directly to the skin surface. Its active component, Trolamine Salicylate, categorizes it pharmacologically as a Topical Salicylate Analgesic, which are agents used to manage localized discomfort. This preparation is a specific type of external Nonsteroidal Anti-inflammatory Drug (NSAID) whose therapeutic action is highly localized.

The topical route is designed to achieve a concentrated effect in the underlying tissue, minimizing the amount of the active ingredient that enters the general circulation. This delivery method ensures the medicine acts primarily at the site of application.

Composition and Form: The Role of Trolamine Salicylate

The formulation's sole active ingredient is Trolamine Salicylate, which is the International Nonproprietary Name (INN) for this manufactured salt. The substance is a chemical derivative of salicylic acid, affirming its synthetic origin.

Bexidermil is supplied as either a Cutaneous Gel or a Cream. These forms utilize a hydrophilic base—a non-oily, water-based vehicle—designed to facilitate skin penetration. This vehicle is essential for facilitating the transport of the Trolamine Salicylate across the skin barrier, localizing the active ingredient to the target area.

General Therapeutic Purpose: What is its Core Benefit?

The fundamental purpose of Bexidermil is to provide local symptomatic relief by delivering the anti-inflammatory and analgesic effects of the Salicylate component directly to the affected area. The medicine's primary benefit is to ease the feeling of discomfort, stiffness, or tenderness associated with common muscle and joint aches.

By modulating the production of inflammatory mediators, which are chemicals that trigger pain signals in the tissue, the preparation helps interrupt the localized pain cycle. The medicine is designed for the localized management of soft tissue discomfort, providing targeted symptomatic comfort without impacting the entire body system.

Regulatory References

  1. DailyMed - NIH

What side effects are possible with Bexidermil?

Possible Side Effects and Safety Information

The safety profile of Bexidermil (Trolamine Salicylate Gel) is primarily characterized by localized adverse reactions, consistent with its topical administration. Official regulatory documents, such as those from the Spanish Agency of Medicines and Medical Devices (AEMPS), list these effects.

Cutaneous Adverse Reactions

Adverse reactions affecting the Skin and Subcutaneous Tissue are the most common safety events. These effects are generally localized to the application area and are classified as Frequency Not Known (a regulatory category meaning a precise frequency cannot be estimated from available data). Documented reactions include local irritation, erythema (redness), and cutaneous sensitization or allergic reactions. The excipient Propylene glycol may also contribute to localized skin irritation, and Methyl parahydroxybenzoate may cause allergic reactions.

Systemic Safety Considerations

While systemic absorption is typically low, the product's official safety profile documents the potential for systemic effects under specific circumstances. The risk of salicylate-type toxicity (salicylism) is noted if the gel is used over extensive areas, for prolonged durations, or when combined with occlusive bandaging or the application of heat. Signs of potential systemic exposure may involve effects like nausea, vomiting, and tinnitus (ringing in the ears).

Safety Restrictions for Specific Groups

The regulatory label outlines specific safety limitations:

  • Hypersensitivity: The medicine is contraindicated for individuals with a history of allergic reactions (e.g., asthma, urticaria) to acetylsalicylic acid or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
  • Pediatrics: Safety and efficacy have not been established in children under 12 years of age.
  • Pregnancy and Lactation: Use during these periods is subject to a formal medical risk assessment, as the active components can be systemically absorbed and cross the placental barrier.

This medication is strictly for external use only, and its simultaneous application with other topical analgesics is not recommended.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations of overdose from the active ingredient, Trolamine Salicylate, which is a systemic risk resulting from accidental ingestion or excessive topical use (salicylate toxicity).

Documented Overdose Manifestations

Symptoms of overdose, based on regulatory information, range from initial indicators to severe complications:

  • Initial Signs: Tinnitus (ringing in the ears), headache, nausea, vomiting, dizziness, and tachypnea (rapid breathing) are common early signs of systemic exposure.
  • Severe Outcomes: Life-threatening manifestations include central nervous system effects (lethargy, confusion, seizures, coma), severe metabolic acidosis, and cardiopulmonary complications like pulmonary edema or respiratory failure.

Required Emergency Actions

Regulatory guidance is explicit regarding the need for immediate professional medical attention in any suspected overdose scenario:

  • Mandatory Help-Seeking: Users must seek immediate medical attention or contact a Poison Control Center immediately for any accidental ingestion or the appearance of overdose symptoms.
  • Hospital Management: Overdose is managed in a hospital setting with supportive measures. Treatment focuses on enhancing elimination, which may involve intravenous fluids for urinary alkalinization or, in severe cases, emergency hemodialysis.
  • Exposure Factors: Urgent referral is warranted for acute ingestions exceeding established toxic thresholds or for patients with renal failure, who may be at increased risk of toxicity from percutaneous absorption.

If any symptoms of systemic toxicity are present, contact emergency services right away.

Therapeutic Uses of Bexidermil

What Bexidermil Treats: Main Uses and Benefits

Bexidermil gel is applied in addressing symptoms related to acute, localized discomfort. It is commonly used when short-term symptomatic assistance is needed, particularly when symptoms intensify and create noticeable physiological strain.

This medication is indicated for easing symptoms related to muscle and joint pain. This includes managing symptoms associated with lumbago, stiff neck (torticolis), muscle contractures, minor trauma, contusions, strains, and mild sprains.

Symptomatic Relief for Muscle and Joint Tension

Bexidermil is applied across domains where additional symptomatic support is needed for muscle and joint tension. The product helps address symptom clusters that may become intense or disruptive, such as those related to sudden muscle stiffness. It offers symptomatic relief that helps patients cope more steadily with temporary functional strain.

Quick Fact: Relief for Acute Localized Discomfort

Supportive Management for Minor Injuries

This product is relevant in conditions characterized by periods of heightened symptoms following minor trauma, including localized strains and bumps. Applying the gel supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load when symptoms interfere with routine activities.

Regulatory References

  1. AEMPS Technical Specification

Eligibility and Restrictions for Use

The official regulatory documentation for Bexidermil (Trolamine Salicylate topical) defines specific populations who can and cannot use the medicine based on safety and established use data.

Eligibility and Exclusion

Population Status Eligibility Rule
Allowed Indicated for adults and adolescents from 12 years of age. Use must be exclusively on intact skin.
Not Recommended Children younger than 12 years are not recommended users as safety and efficacy have not been established.
Contraindicated Use is prohibited in patients with known hypersensitivity to the active ingredient, Trolamine Salicylate, or a history of allergic reactions to Aspirin or other NSAIDs due to cross-reactivity risk.

Conditional Use and Restrictions

Use is strictly prohibited on open wounds, eroded skin, burns, or mucous membranes. The medicine must not be applied over extensive areas of the body or covered with occlusive bandages or local heat, as these practices increase the risk of systemic absorption.

Regarding physiological status, the safety of Bexidermil use during both pregnancy and lactation is not established, and use is generally not recommended, particularly during the late stages of pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Bexidermil (Trolamine Salicylate) as stated in authoritative government regulatory sources.

Documented Pharmacodynamic Interactions

Co-administration with oral anticoagulants, such as Warfarin and Acenocumarol, warrants careful consideration. This caution is due to the potential for the potentiation of anticoagulant effects (increased blood-thinning activity). However, regulatory documentation notes that this interaction is considered improbable because of the low systemic concentrations of Trolamine Salicylate achieved with the topical route of administration.

Timing-Based and Product-Based Restrictions

Simultaneous application of Bexidermil with other topical analgesics or rubefacients on the same affected area is not recommended. This restriction is in place because co-administration may lead to an additive potentiation of effects in the treated region.

Furthermore, the use of occlusive bandages or the application of heat to the treatment area is restricted. These conditions can increase the systemic absorption of the active ingredient through the skin, which may alter its exposure profile.

Mechanism of Action

The localized physiological effect of Trolamine Salicylate is driven by two main, interconnected biological actions that occur directly in the affected tissue.

Enzyme Inhibition and Prostaglandin Blockade

This domain covers the drug's action on its primary biological targets: the Cyclooxygenase ( COX) enzymes. The salicylate component acts as a non-selective inhibitor of COX-1 and COX-2, thereby interrupting the Arachidonic Acid Cascade. This molecular blockade prevents the local biosynthesis of pro-inflammatory mediators, primarily prostaglandins ( PGE2), which limits the generation of these mediators.

Modulation of Peripheral Nociceptive Signaling

The subsequent physiological effect is the functional desensitization of peripheral nociceptors. By reducing the local concentration of sensitizing prostaglandins, the drug raises the activation threshold of these nerve endings. This physiological shift limits the overactive signaling within the peripheral system, which is the basis for the drug's physiological effect on nociceptive signal transmission.

Constraint via Topical Delivery

The mechanism is intrinsically limited by the topical route. The necessity for the active component to partition and penetrate the skin barrier (stratum corneum) influences the concentration gradient achievable. Consequently, the drug’s ability to modulate the physiological responses is primarily limited to superficial and sub-dermal physiological responses.

Dosage and Administration Information

How to use Bexidermil: Official Administration Guidelines

Administration Scope Details
Route of administration Topical (Cutaneous), designated exclusively for external use.
Dosing schedule Apply a thin, generous layer of the gel or cream to the affected area, massaging until the product is thoroughly absorbed into the skin.
Frequency and timing Applications may be repeated as necessary, but must not exceed 3 to 4 times daily. The final application of the day is often advised before bedtime.
Age-group rules The standard regimen is for adults and adolescents 12 years of age and older. Use is not recommended for children younger than 12, as safety and efficacy have not been established.
Course duration The product is intended for short-term use. Use should be discontinued if symptoms persist for more than 7 days, requiring clinical review.

Official Procedural Instructions

Special procedural conditions:

  • Application must be strictly limited to intact skin and should not be used on wounds, damaged, or irritated areas.
  • Contact with the eyes or mucous membranes must be avoided during application.
  • Hands must be washed immediately following each application of the product.

Connection to the Overall Use Protocol

These official instructions structure the use of the topical analgesic as a highly localized, procedural application. The specific frequency and 7-day duration limit establish a clear boundary for the short-term treatment course, while the route and application restrictions ensure the standardized administration of the 100 mg/g formulation. The guidelines govern the standardized approach to its use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Research

Research has extensively explored the compound's potential application in managing symptoms associated with chronic joint conditions. Studies evaluated the analgesic effect and investigated whether it influences joint function and mobility in various populations. Studies explored this treatment; the occurrence of side effects was also documented.

Key Clinical Findings

Analgesic Activity and Symptom Change

A series of randomized controlled trials (RCTs) focused on the compound's activity. The primary endpoint in these investigations was often the change in pain scores, with studies exploring the potential for a change in pain intensity over various treatment durations.

  • Initial Trials: Early-stage trials focused on dose-ranging, and initial findings were mixed regarding the optimal concentration. Trials reported observations of changes in symptom scores for a portion of the study participants.
  • Long-Term Follow-up: Studies involving treatment over six months or more examined the long-term profile of the compound. The time to onset of symptom change was a focus of investigation in these trials, with researchers aiming to characterize the course of symptom changes.

Studies on Combination Therapy

Research has also investigated the compound when administered as part of a combination regimen. The simple dosing schedule was noted in these studies; researchers also explored its influence on patient compliance. Studies have evaluated its use in people with moderate arthritis to establish a comprehensive clinical profile.

Safety and Monitoring Profile

The research program has consistently collected data on adverse events. Studies have noted that individuals with a history of liver issues were excluded or were subject to specific monitoring in research protocols. Standard monitoring protocols were established during the development phase.

How should Bexidermil be stored and disposed of?

How to Store and Dispose of Bexidermil?

The storage and disposal of Bexidermil are governed by mandatory regulatory requirements to maintain the stability of the active ingredient, Trolamine Salicylate, and ensure public safety.

Official Storage Requirements

Storage Component Requirement
Temperature Store the medicinal product below 30°C.
Packaging Keep the product in its original package.
Child Safety Keep this medicine out of the sight and reach of children.

Storage above the mandated temperature may compromise product stability.

Disposal Instructions

Unused or expired Bexidermil must not be discarded with household waste or disposed of by pouring it into drains or wastewater. The product must be taken to the designated pharmaceutical waste collection point (such as a SIGRE Point) at a pharmacy, following local environmental regulations for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSpain

Equivalent of Bexidermil found in:

A-Z Index: